GlycoMimetics Historical Balance Sheet

GLYC Stock

USD 0.23 0.01 2.87%

Trend analysis of GlycoMimetics balance sheet accounts such as Total Current Liabilities of 9.5 M or Total Stockholder Equity of 36.5 M provides information on GlycoMimetics' total assets, liabilities, and equity, which is the actual value of GlycoMimetics to its prevalent stockholders. By breaking down trends over time using GlycoMimetics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining GlycoMimetics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether GlycoMimetics is a good buy for the upcoming year.

GlycoMimetics Inventory

(136,455)

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlycoMimetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For information on how to trade GlycoMimetics Stock refer to our How to Trade GlycoMimetics Stock guide.

About GlycoMimetics Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of GlycoMimetics at a specified time, usually calculated after every quarter, six months, or one year. GlycoMimetics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of GlycoMimetics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which GlycoMimetics currently owns. An asset can also be divided into two categories, current and non-current.

GlycoMimetics Balance Sheet Chart

At present, GlycoMimetics' Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 9.5 M, whereas Total Stockholder Equity is forecasted to decline to about 36.5 M.

Total Assets Other Current Liab Total Current Liabilities Total Stockholder Equity

Add Fundamental

Total Assets

Total assets refers to the total amount of GlycoMimetics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in GlycoMimetics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on GlycoMimetics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of GlycoMimetics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most accounts from GlycoMimetics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into GlycoMimetics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlycoMimetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For information on how to trade GlycoMimetics Stock refer to our How to Trade GlycoMimetics Stock guide.At present, GlycoMimetics' Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 9.5 M, whereas Total Stockholder Equity is forecasted to decline to about 36.5 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	8.7M	7.0M	5.2M	6.0M
Total Assets	94.3M	51.8M	45.3M	88.5M

Other Current Liab Total Assets

GlycoMimetics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Property Plant Equipment	Net Tangible Assets
Total Assets		0.66	0.18	0.98	-0.26	0.66	-0.32	-0.98	-0.33	0.79	0.98	0.74	0.63	0.03	0.98	0.59	0.55	0.03	0.41	0.63	0.16	0.46	1.0	0.56	0.37	0.94
Other Current Liab	0.66		0.04	0.65	-0.58	0.74	-0.59	-0.63	-0.63	0.51	0.63	0.8	0.62	0.18	0.63	0.79	0.81	-0.16	0.33	0.78	-0.03	0.75	0.65	0.79	0.6	0.44
Total Current Liabilities	0.18	0.04		0.09	0.75	0.2	0.75	-0.18	-0.06	-0.06	0.18	0.25	0.08	0.37	0.18	-0.02	0.0	0.86	0.12	0.08	0.99	0.21	0.18	-0.04	-0.09	0.15
Total Stockholder Equity	0.98	0.65	0.09		-0.31	0.64	-0.36	-1.0	-0.26	0.79	1.0	0.71	0.61	0.02	1.0	0.54	0.55	-0.01	0.41	0.62	0.07	0.47	0.98	0.56	0.38	0.96
Other Liab	-0.26	-0.58	0.75	-0.31		-0.36	0.99	0.23	0.42	-0.36	-0.23	-0.35	-0.4	0.13	-0.23	-0.56	-0.51	0.8	-0.12	-0.45	0.79	-0.35	-0.26	-0.54	-0.45	-0.16
Property Plant And Equipment Net	0.66	0.74	0.2	0.64	-0.36		-0.36	-0.62	-0.47	0.47	0.63	0.95	0.68	0.12	0.63	0.59	0.57	0.19	0.72	0.63	0.21	0.8	0.65	0.57	0.38	0.57
Current Deferred Revenue	-0.32	-0.59	0.75	-0.36	0.99	-0.36		0.28	0.42	-0.45	-0.28	-0.35	-0.39	0.14	-0.28	-0.59	-0.53	0.81	-0.1	-0.47	0.79	-0.33	-0.32	-0.57	-0.51	-0.2
Net Debt	-0.98	-0.63	-0.18	-1.0	0.23	-0.62	0.28		0.23	-0.78	-1.0	-0.7	-0.6	-0.05	-1.0	-0.51	-0.52	-0.06	-0.39	-0.6	-0.15	-0.45	-0.98	-0.53	-0.35	-0.96
Retained Earnings	-0.33	-0.63	-0.06	-0.26	0.42	-0.47	0.42	0.23		-0.3	-0.23	-0.49	-0.37	-0.18	-0.23	-0.93	-0.89	0.16	-0.09	-0.89	0.01	-0.59	-0.32	-0.89	-0.66	-0.12
Accounts Payable	0.79	0.51	-0.06	0.79	-0.36	0.47	-0.45	-0.78	-0.3		0.77	0.55	0.55	0.24	0.77	0.53	0.46	-0.24	0.03	0.53	-0.09	0.39	0.79	0.5	0.6	0.74
Cash	0.98	0.63	0.18	1.0	-0.23	0.63	-0.28	-1.0	-0.23	0.77		0.71	0.6	0.05	1.0	0.51	0.52	0.07	0.4	0.6	0.16	0.47	0.98	0.53	0.35	0.96
Non Current Assets Total	0.74	0.8	0.25	0.71	-0.35	0.95	-0.35	-0.7	-0.49	0.55	0.71		0.84	0.27	0.71	0.64	0.63	0.12	0.61	0.68	0.24	0.79	0.72	0.62	0.49	0.63
Non Currrent Assets Other	0.63	0.62	0.08	0.61	-0.4	0.68	-0.39	-0.6	-0.37	0.55	0.6	0.84		0.43	0.6	0.5	0.48	-0.14	0.33	0.53	0.06	0.58	0.62	0.47	0.52	0.57
Other Assets	0.03	0.18	0.37	0.02	0.13	0.12	0.14	-0.05	-0.18	0.24	0.05	0.27	0.43		0.05	0.1	0.17	0.12	-0.11	0.19	0.32	0.46	0.02	0.15	0.61	0.01
Cash And Short Term Investments	0.98	0.63	0.18	1.0	-0.23	0.63	-0.28	-1.0	-0.23	0.77	1.0	0.71	0.6	0.05		0.51	0.52	0.07	0.4	0.6	0.16	0.47	0.98	0.53	0.35	0.96
Common Stock Total Equity	0.59	0.79	-0.02	0.54	-0.56	0.59	-0.59	-0.51	-0.93	0.53	0.51	0.64	0.5	0.1	0.51		0.94	-0.28	0.17	0.93	-0.09	0.6	0.59	0.95	0.71	0.37
Common Stock Shares Outstanding	0.55	0.81	0.0	0.55	-0.51	0.57	-0.53	-0.52	-0.89	0.46	0.52	0.63	0.48	0.17	0.52	0.94		-0.19	0.2	0.98	-0.08	0.68	0.54	0.99	0.74	0.37
Non Current Liabilities Total	0.03	-0.16	0.86	-0.01	0.8	0.19	0.81	-0.06	0.16	-0.24	0.07	0.12	-0.14	0.12	0.07	-0.28	-0.19		0.31	-0.09	0.9	0.19	0.02	-0.23	-0.34	0.1
Other Current Assets	0.41	0.33	0.12	0.41	-0.12	0.72	-0.1	-0.39	-0.09	0.03	0.4	0.61	0.33	-0.11	0.4	0.17	0.2	0.31		0.25	0.18	0.47	0.4	0.18	0.02	0.42
Other Stockholder Equity	0.63	0.78	0.08	0.62	-0.45	0.63	-0.47	-0.6	-0.89	0.53	0.6	0.68	0.53	0.19	0.6	0.93	0.98	-0.09	0.25		0.01	0.73	0.62	0.98	0.71	0.49
Total Liab	0.16	-0.03	0.99	0.07	0.79	0.21	0.79	-0.15	0.01	-0.09	0.16	0.24	0.06	0.32	0.16	-0.09	-0.08	0.9	0.18	0.01		0.17	0.15	-0.11	-0.17	0.15
Property Plant And Equipment Gross	0.46	0.75	0.21	0.47	-0.35	0.8	-0.33	-0.45	-0.59	0.39	0.47	0.79	0.58	0.46	0.47	0.6	0.68	0.19	0.47	0.73	0.17		0.45	0.67	0.63	0.36
Total Current Assets	1.0	0.65	0.18	0.98	-0.26	0.65	-0.32	-0.98	-0.32	0.79	0.98	0.72	0.62	0.02	0.98	0.59	0.54	0.02	0.4	0.62	0.15	0.45		0.55	0.37	0.94
Common Stock	0.56	0.79	-0.04	0.56	-0.54	0.57	-0.57	-0.53	-0.89	0.5	0.53	0.62	0.47	0.15	0.53	0.95	0.99	-0.23	0.18	0.98	-0.11	0.67	0.55		0.75	0.39
Property Plant Equipment	0.37	0.6	-0.09	0.38	-0.45	0.38	-0.51	-0.35	-0.66	0.6	0.35	0.49	0.52	0.61	0.35	0.71	0.74	-0.34	0.02	0.71	-0.17	0.63	0.37	0.75		0.22
Net Tangible Assets	0.94	0.44	0.15	0.96	-0.16	0.57	-0.2	-0.96	-0.12	0.74	0.96	0.63	0.57	0.01	0.96	0.37	0.37	0.1	0.42	0.49	0.15	0.36	0.94	0.39	0.22

Click cells to compare fundamentals

GlycoMimetics Account Relationship Matchups

GlycoMimetics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	168.0M	142.8M	94.3M	51.8M	45.3M	88.5M
Other Current Liab	8.7M	9.4M	8.7M	7.0M	5.2M	6.0M
Total Current Liabilities	11.0M	12.4M	11.8M	8.9M	6.8M	9.5M
Total Stockholder Equity	154.2M	128.2M	81.6M	42.9M	38.4M	36.5M
Property Plant And Equipment Net	3.8M	2.9M	1.9M	993.6K	767.8K	1.3M
Net Debt	(154.6M)	(134.2M)	(88.3M)	(47.0M)	(41.0M)	(43.0M)
Retained Earnings	(258.4M)	(309.5M)	(372.9M)	(419.6M)	(456.5M)	(433.7M)
Accounts Payable	1.4M	2.1M	2.1M	970.2K	868.1K	1.5M
Cash	158.2M	137.0M	90.3M	47.9M	41.8M	39.7M
Non Current Assets Total	5.4M	4.6M	4.1M	1.1M	1.5M	2.2M
Other Assets	321.0	(169.0)	1.6M	411.0	1.0	0.95
Cash And Short Term Investments	158.2M	137.0M	90.3M	47.9M	41.8M	39.7M
Common Stock Total Equity	34.4K	43.2K	43.5K	49.0K	56.4K	59.2K
Common Stock Shares Outstanding	43.3M	45.7M	51.5M	52.5M	63.3M	32.9M
Liabilities And Stockholders Equity	168.0M	142.8M	94.3M	51.8M	45.3M	88.5M
Non Current Liabilities Total	2.8M	2.2M	918.6K	1.9M	66.8K	63.5K
Other Current Assets	4.3B	1.2M	532.5K	2.7M	1.8M	1.7M
Other Stockholder Equity	412.6M	437.6M	454.4M	462.5M	494.8M	300.5M
Total Liab	13.8M	14.6M	12.7M	8.9M	6.9M	10.6M
Property Plant And Equipment Gross	3.8M	2.9M	4.3M	3.4M	767.8K	729.4K
Total Current Assets	162.5M	138.3M	90.3M	50.7M	43.8M	86.3M
Common Stock	43.5K	49.0K	52.3K	54.4K	64.4K	35.1K
Property Plant Equipment	822.9K	620.7K	1.9M	993.6K	1.1M	876.5K
Net Tangible Assets	154.2M	128.2M	81.6M	42.9M	49.4M	46.9M
Net Receivables	186.0K	2.1K	1.3K	144.0K	175.8K	148.9K
Retained Earnings Total Equity	(152.3M)	(200.6M)	(258.4M)	(309.5M)	(278.5M)	(264.6M)
Capital Surpluse	271.9M	406.0M	412.6M	437.6M	503.3M	304.1M
Inventory	(4.3B)	(1.2B)	(533.8M)	(144.4K)	(130.0K)	(136.5K)
Net Invested Capital	154.2M	128.2M	81.6M	42.9M	38.4M	36.5M
Net Working Capital	151.6M	125.8M	79.0M	41.8M	37.0M	35.1M
Capital Stock	43.5K	49.0K	52.3K	54.4K	64.4K	56.2K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether GlycoMimetics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of GlycoMimetics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Glycomimetics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Glycomimetics Stock:

How To Invest In GlycoMimetics

Details

Is GlycoMimetics Stock a good investment?

Details

What is GlycoMimetics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade GlycoMimetics Stock refer to our How to Trade GlycoMimetics Stock guide.

You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlycoMimetics. If investors know GlycoMimetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlycoMimetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.62)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.59)

Return On Equity

(1.04)

The market value of GlycoMimetics is measured differently than its book value, which is the value of GlycoMimetics that is recorded on the company's balance sheet. Investors also form their own opinion of GlycoMimetics' value that differs from its market value or its book value, called intrinsic value, which is GlycoMimetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlycoMimetics' market value can be influenced by many factors that don't directly affect GlycoMimetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between GlycoMimetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if GlycoMimetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlycoMimetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

GlycoMimetics Historical Balance Sheet

GlycoMimetics Inventory

(136,455)

About GlycoMimetics Balance Sheet Analysis

GlycoMimetics Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

GlycoMimetics balance sheet Correlations

GlycoMimetics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

GlycoMimetics balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Total Liab	+ 0.99	Total Current Liabilities
Current Deferred Revenue	+ 0.99	Other Liab

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Stockholder Equity
Total Current Assets	- 0.98	Net Debt
Net Debt	- 0.98	Total Assets
Net Tangible Assets	- 0.96	Net Debt